Login to Your Account



Hatchtech Adds $7.8M, Preps for Phase III Trial of DeOvo

By Nuala Moran
Staff Writer

Wednesday, May 16, 2012
LONDON – HatchTech Pty. Ltd. raised A$7.8 million (US$7.8 million) from existing investors, enabling it to push DeOvo, a metalloproteinase inhibitor for treating head lice, into a Phase III U.S. trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription